BLT.AX says CEO and Managing Director Dr Peter French Resigned, page-36

Dr. KSS MD PhD, author of this article, says:
December 9, 2015 at 10:44 am

Honor Roll Post of the Day!
To give a little insight on the situation, what I feel has happened is that they have advanced enough to sufficiently high doses of TT-034 such that they are in what should be therapeutic range…..and are seeing no effect on patient HCV RNA viral burden. Accordingly, French has bum-steered them. They have languished two years in but one clinical project and it is a bust. Oh, and French would have loved a gig as a US CEO. The board turned against him. They had to. With what’s been gained in knowledge, moreover, in the new HBV race, I think heads wiser than French’s are realizing that a ddRNAi therapeutic alone against HBV has almost no chance of working.
With correct inclusion of clinicians early in their planning, and with a genuine CEO with CEO qualities, this could have been a royally hot superstar biotech. Now, however, I cannot see them even being extant in 2017 and beyond.